By Jenny Strasburg
LONDON — The biotech startup behind the Covid-19 vaccine jointly developed by AstraZeneca PLC and the University of Oxford filed Friday with U.S. regulators for a public share offering.
Vaccitech PLC said in a securities filing it plans to use the technology underpinning the vaccine to develop treatments targeting prostate cancer, hepatitis B and human papillomavirus. The Wall Street Journal reported Wednesday that the IPO filing could come as soon as this week. The U.K.-based company plans to list on New York’s Nasdaq with the ticker symbol VACC.
(END) Dow Jones Newswires
April 09, 2021 18:42 ET (22:42 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.